News | June 09, 2021
Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Subscribe To Our Newsletter & Stay Updated
